Rury R. Holman, FMedSci, Receives American Diabetes Association’s® 2018 Outstanding Achievement in Clinical Diabetes Research Award

Contact

Michelle Kirkwood
press@diabetes.org
703-299-2053

Arlington, Virginia
May 11, 2018

The American Diabetes Association® (ADA) will present the 2018 Outstanding Achievement in Clinical Diabetes Research Award to Rury R. Holman, FMedSci. This award recognizes exceptional contributions in patient-oriented or clinical outcomes research that have had a significant impact on diabetes prevention and treatment. Dr. Holman will be recognized with this honor during the ADA’s 78th Scientific Sessions, June 22-26, 2018, at the Orange County Convention Center in Orlando.

Dr. Holman is currently Professor of Diabetic Medicine at the University of Oxford, Director of the University of Oxford Diabetes Trial Unit and a National Institute for Health Research Senior Investigator. Having delivered landmark clinical outcome trials for more than four decades, Dr. Holman is an exemplary clinical scientist and global leader in the field of diabetes.

“I would like to congratulate Dr. Holman and humbly thank him for his remarkable research contributions, which have shaped the way we approach diabetes care and informed evidence-based strategies to prevent and treat diabetes,” said the ADA’s 2018 President of Medicine and Science Jane E.B. Reusch, MD. “Dr. Holman’s work has led to crucial advancements in diabetes treatment and touched millions of lives in the process.”

With more than 300 publications and more than 55,000 citations, Dr. Holman has been recognized as one of the top 400 biomedical researchers and one of the world’s most influential scientific minds. Dr. Holman’s major accomplishments include:

  • Pioneering studies in the use of basal insulin therapy for type 2 diabetes;
  • Co-inventing the first automated finger-pricker, enabling home blood glucose monitoring and the first automated insulin pen, as well as the HOMA Calculator;
  • Co-designing and operating the 20-year UK Prospective Diabetes Study (UKPDS), which ushered in the modern era of diabetes risk factor management; and
  • Directing the 10-year UKPDS post-trial monitoring program that identified the glucose “legacy effect,” which led guidelines worldwide to recommend targeting optimal blood glucose control immediately upon diagnosis of diabetes.

The American Diabetes Association’s 78th Scientific Sessions, to be held June 22-26, 2018, at the Orange County Convention Center in Orlando, is the world’s largest scientific meeting focused on diabetes research, prevention and care. During the five-day meeting, more than 16,000 health care professionals from around the world will have exclusive access to more than 3,000 original diabetes research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight theme areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Felicia Hill-Briggs, PhD, ABPP, President of Health Care and Education, will deliver her address, “The American Diabetes Association in the Era of Health Care Transformation,” on Saturday, June 23, and Jane E.B. Reusch, MD, President of Medicine and Science, will present her address, “24/7/365 – Lifetime with Diabetes,” on Sunday, June 24. In total, the 2018 Scientific Sessions includes 375 oral presentations; 2,117 poster presentations, including 47 moderated poster discussions; and 297 published-only abstracts. Join the Scientific Sessions conversation on social media using #2018ADA.